Repare Therapeutics Inc (NASDAQ: RPTX) stock fell -9.71% on Friday to $5.02 against a previous-day closing price of $5.56. With 0.6 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.29 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $5.69 whereas the lowest price it dropped to was $4.96. The 52-week range on RPTX shows that it touched its highest point at $18.68 and its lowest point at $3.08 during that stretch. It currently has a 1-year price target of $23.50. Beta for the stock currently stands at 0.48.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RPTX was up-trending over the past week, with a rise of 30.73%, but this was up by 11.06% over a month. Three-month performance dropped to -51.45% while six-month performance fell -46.99%. The stock lost -70.47% in the past year, while it has lost -65.87% so far this year. A look at the trailing 12-month EPS for RPTX yields -2.32 with Next year EPS estimates of -3.37. For the next quarter, that number is -0.32. This implies an EPS growth rate of -194.20% for this year and -66.17% for next year.
Float and Shares Shorts:
At present, 42.04 million RPTX shares are outstanding with a float of 31.81 million shares on hand for trading. On Oct 30, 2023, short shares totaled 1.74 million, which was 4.13% higher than short shares on Sep 28, 2023. In addition to RTX as the firm’s RTX Corporation, OPTX serves as its Syntec Optics Holdings, Inc..
Through their ownership of 88.19% of RPTX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 55.02% of RPTX, in contrast to 52.14% held by mutual funds. Shares owned by individuals account for 13.67%. As the largest shareholder in RPTX with 21.62% of the stake, BVF Partners LP holds 9,098,600 shares worth 9,098,600. A second-largest stockholder of RPTX, Deep Track Capital LP, holds 3,067,731 shares, controlling over 7.29% of the firm’s shares. CHI Advisors LLC is the third largest shareholder in RPTX, holding 2,966,674 shares or 7.05% stake. With a 6.06% stake in RPTX, the ARK Genomic Revolution ETF is the largest stakeholder. A total of 2,552,364 shares are owned by the mutual fund manager. The T Rowe Price Small Cap Value Fund, which owns about 1.46% of RPTX stock, is the second-largest Mutual Fund holder. It holds 615,139 shares valued at 2.09 million. FCP Medical – BioHealth holds 1.10% of the stake in RPTX, owning 464,032 shares worth 1.58 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RPTX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With RPTX analysts setting a high price target of $31.00 and a low target of $12.00, the average target price over the next 12 months is $23.50. Based on these targets, RPTX could surge 517.53% to reach the target high and rise by 139.04% to reach the target low. Reaching the average price target will result in a growth of 368.13% from current levels.
Summary of Insider Activity:
Insiders traded RPTX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 16 while that of sell transactions has risen to 12 over the past year. The total number of shares bought during that period was 333,149 while 419,159 shares were sold.